New Vaccine facility

Producing today the vaccines that will protect Canada tomorrow.

Moderna’s new facility manufactures vaccines for a range of diseases, including COVID-19, seasonal influenza, and other potential respiratory viruses. The new site includes a research center and an mRNA vaccine manufacturing plant, with an initial production capacity of 30 million vaccine doses per year, increasing to 100 million doses annually. The facility significantly expands advanced biomanufacturing capacity worldwide while enabling Canada to better prepare for future pandemics.

This project provides the country with state-of-the-art facilities and production capacity, allowing accelerated access to large-scale mRNA vaccines. As Moderna’s first manufacturing facility outside the United States, it enables national self-sufficiency in mRNA vaccines.